Ogden Christopher, CFO of CytomX Therapeutics ($CTMX), made three open market sales of company shares over the last year, totaling roughly $38,500. His most recent sale occurred on June 16, 2025. These transactions rank 10,638th among 11,678 insiders by sale value, well below the average of 8.6 million per insider across 6.4 transactions. He recorded no open market purchases.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 17, 2026 | CytomX Therapeutics, Inc. | $CTMX | Ogden Christopher | Chief Financial Officer | S | Common Stock | 19323 | $6.42 | 296,948.0000 | 169,435,395 | 6.11% | 0.01% |
| Feb. 2, 2026 | CytomX Therapeutics, Inc. | $CTMX | Ogden Christopher | Chief Financial Officer | A | Common Stock | 90000 | $0.00 | 316,271.0000 | 169,435,395 | 39.78% | 0.05% |
| Feb. 2, 2026 | CytomX Therapeutics, Inc. | $CTMX | Ogden Christopher | Chief Financial Officer | A | Stock Option (Right to Buy) | 325000 | $0.00 | 325,000.0000 | 169,435,395 | 9999.99% | 0.19% |
| Sept. 26, 2025 | CytomX Therapeutics, Inc. | $CTMX | Ogden Christopher | Chief Financial Officer | A | Performance Stock Units (PSUs) | 39150 | $0.00 | 39,150.0000 | 80,099,889 | 9999.99% | 0.05% |
| Sept. 26, 2025 | CytomX Therapeutics, Inc. | $CTMX | Ogden Christopher | Chief Financial Officer | A | Stock Option (Right to Buy) | 78250 | $0.00 | 78,250.0000 | 80,099,889 | 9999.99% | 0.10% |
| June 13, 2025 | CytomX Therapeutics, Inc. | $CTMX | Ogden Christopher | Chief Financial Officer | S | Common Stock | 1641 | $2.95 | 199,385.0000 | 80,099,889 | 0.82% | 0.00% |
| June 13, 2025 | CytomX Therapeutics, Inc. | $CTMX | Ogden Christopher | Chief Financial Officer | M | Common Stock | 37500 | $0.00 | 236,885.0000 | 80,099,889 | 18.81% | 0.05% |
| June 16, 2025 | CytomX Therapeutics, Inc. | $CTMX | Ogden Christopher | Chief Financial Officer | S | Common Stock | 10614 | $2.69 | 226,271.0000 | 80,099,889 | 4.48% | 0.01% |
| June 13, 2025 | CytomX Therapeutics, Inc. | $CTMX | Ogden Christopher | Chief Financial Officer | M | Performance Stock Units | 37500 | $0.00 | 0.0000 | 80,099,889 | 100.00% | 0.05% |
| March 18, 2025 | CytomX Therapeutics, Inc. | $CTMX | Ogden Christopher | Chief Financial Officer | S | Common Stock | 8551 | $0.60 | 201,026.0000 | 80,099,889 | 4.08% | 0.01% |
| Feb. 4, 2025 | CytomX Therapeutics, Inc. | $CTMX | Ogden Christopher | Chief Financial Officer | A | Common Stock | 57500 | $0.00 | 209,577.0000 | 0 | 37.81% | 0.00% |
| Feb. 4, 2025 | CytomX Therapeutics, Inc. | $CTMX | Ogden Christopher | Chief Financial Officer | A | Stock Option (Right to Buy) | 225000 | $0.00 | 225,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 4, 2025 | CytomX Therapeutics, Inc. | $CTMX | Ogden Christopher | Chief Financial Officer | A | Stock Option (Right to Buy) | 115000 | $0.00 | 115,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 4, 2025 | CytomX Therapeutics, Inc. | $CTMX | Ogden Christopher | Chief Financial Officer | A | Common Stock | 44000 | $0.00 | 152,077.0000 | 0 | 40.71% | 0.00% |
| Aug. 20, 2024 | CytomX Therapeutics, Inc. | $CTMX | Ogden Christopher | Chief Financial Officer | M | Common Stock | 6875 | $0.00 | 110,061.0000 | 0 | 6.66% | 0.00% |
| Aug. 20, 2024 | CytomX Therapeutics, Inc. | $CTMX | Ogden Christopher | Chief Financial Officer | S | Common Stock | 1984 | $1.23 | 108,077.0000 | 0 | 1.80% | 0.00% |
| Aug. 20, 2024 | CytomX Therapeutics, Inc. | $CTMX | Ogden Christopher | Chief Financial Officer | M | Performance Stock Units (PSUs) | 6875 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| June 12, 2024 | CytomX Therapeutics, Inc. | $CTMX | Ogden Christopher | Chief Financial Officer | A | Stock Option (Right to Buy) | 75000 | $0.00 | 75,000.0000 | 0 | 9999.99% | 0.00% |
| June 12, 2024 | CytomX Therapeutics, Inc. | $CTMX | Ogden Christopher | Chief Financial Officer | A | Common Stock | 17500 | $0.00 | 103,186.0000 | 0 | 20.42% | 0.00% |
| March 19, 2024 | CytomX Therapeutics, Inc. | $CTMX | Ogden Christopher | SVP, Finance and Accounting | S | Common Stock | 2971 | $2.09 | 85,686.0000 | 0 | 3.35% | 0.00% |
| Jan. 18, 2024 | CytomX Therapeutics, Inc. | $CTMX | Ogden Christopher | SVP, Finance and Accounting | A | Performance Stock Units (PSUs) | 75000 | $0.00 | 75,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 18, 2024 | CytomX Therapeutics, Inc. | $CTMX | Ogden Christopher | SVP, Finance and Accounting | A | Stock Option (Right to Buy) | 154000 | $0.00 | 154,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 18, 2024 | CytomX Therapeutics, Inc. | $CTMX | Ogden Christopher | SVP, Finance and Accounting | A | Common Stock | 40000 | $0.00 | 88,657.0000 | 0 | 82.21% | 0.00% |